TP53 deletion

News alerts, weekly reports and conference planners

Entrez ID:

7157

Related biomarkers:

‹

›

TP53 deletion	Chronic Lymphocytic Leukemia	TP53 deletion	Chronic Lymphocytic Leukemia	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
TP53 deletion	Chronic Lymphocytic Leukemia	TP53 deletion	Chronic Lymphocytic Leukemia	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 deletion	Chronic Lymphocytic Leukemia	TP53 deletion	Chronic Lymphocytic Leukemia	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2	rituximab Sensitive: A2 - Guideline rituximab Sensitive : A2
TP53 deletion	Small Lymphocytic Lymphoma	TP53 deletion	Small Lymphocytic Lymphoma	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2	ibrutinib Sensitive: A2 - Guideline ibrutinib Sensitive : A2
TP53 deletion	Prostate Cancer	TP53 deletion	Prostate Cancer	abiraterone acetate Resistant: B - Late Trials abiraterone acetate Resistant : B	abiraterone acetate Resistant: B - Late Trials abiraterone acetate Resistant : B
TP53 deletion	Prostate Cancer	TP53 deletion	Prostate Cancer	enzalutamide Resistant: B - Late Trials enzalutamide Resistant : B	enzalutamide Resistant: B - Late Trials enzalutamide Resistant : B
TP53 deletion	Chronic Lymphocytic Leukemia	TP53 deletion	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Sensitive: C2 – Inclusion Criteria venetoclax + obinutuzumab Sensitive : C2	venetoclax + obinutuzumab Sensitive: C2 – Inclusion Criteria venetoclax + obinutuzumab Sensitive : C2
TP53 deletion	Melanoma	TP53 deletion	Melanoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
TP53 deletion	B Acute Lymphoblastic Leukemia	TP53 deletion	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
TP53 deletion	Mantle Cell Lymphoma	TP53 deletion	Mantle Cell Lymphoma	venetoclax + ibrutinib + rituximab Sensitive: C3 – Early Trials venetoclax + ibrutinib + rituximab Sensitive : C3	venetoclax + ibrutinib + rituximab Sensitive: C3 – Early Trials venetoclax + ibrutinib + rituximab Sensitive : C3
TP53 deletion	Peripheral T-cell Lymphoma	TP53 deletion	Peripheral T-cell Lymphoma	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
TP53 deletion	Diffuse Large B Cell Lymphoma	TP53 deletion	Diffuse Large B Cell Lymphoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
TP53 deletion	Marginal Zone Lymphoma	TP53 deletion	Marginal Zone Lymphoma	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3	ibrutinib Resistant: C3 – Early Trials ibrutinib Resistant : C3
TP53 deletion	Chronic Lymphocytic Leukemia	TP53 deletion	Chronic Lymphocytic Leukemia	ONC212 Sensitive: D – Preclinical ONC212 Sensitive : D	ONC212 Sensitive: D – Preclinical ONC212 Sensitive : D
TP53 deletion	Colorectal Cancer	TP53 deletion	Colorectal Cancer	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D
TP53 deletion	Non Small Cell Lung Cancer	TP53 deletion	Non Small Cell Lung Cancer	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D
TP53 deletion	Mantle Cell Lymphoma	TP53 deletion	Mantle Cell Lymphoma	venetoclax Resistant: D – Preclinical venetoclax Resistant : D	venetoclax Resistant: D – Preclinical venetoclax Resistant : D
TP53 deletion	B Acute Lymphoblastic Leukemia	TP53 deletion	B Acute Lymphoblastic Leukemia	romidepsin Sensitive: D – Preclinical romidepsin Sensitive : D	romidepsin Sensitive: D – Preclinical romidepsin Sensitive : D
TP53 deletion	Lymphoma	TP53 deletion	Lymphoma	crizotinib Resistant: D – Preclinical crizotinib Resistant : D	crizotinib Resistant: D – Preclinical crizotinib Resistant : D
TP53 deletion	Lymphoma	TP53 deletion	Lymphoma	brigatinib Sensitive: D – Preclinical brigatinib Sensitive : D	brigatinib Sensitive: D – Preclinical brigatinib Sensitive : D
TP53 deletion	Acute Lymphocytic Leukemia	TP53 deletion	Acute Lymphocytic Leukemia	M6620 + BAY2402234 Sensitive: D – Preclinical M6620 + BAY2402234 Sensitive : D	M6620 + BAY2402234 Sensitive: D – Preclinical M6620 + BAY2402234 Sensitive : D

TP53 deletion

Associations